MBG453 platform study in myelofibrosis
Research type
Research Study
Full title
A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select combinations in adult patients with myelofibrosis
IRAS ID
281028
Contact name
David Sampson
Contact email
Sponsor organisation
Novartis Pharma AG
Eudract number
2019-003738-18
Clinicaltrials.gov Identifier
Duration of Study in the UK
3 years, 3 months, 31 days
Research summary
Myelofibrosis (MF) is a type of blood cancer that affects the bone marrow. In people with MF, scar tissue builds up inside the bone marrow and blood cells are not made properly. MF can happen at any age, but it is most common in people over the age of 50.To make up for the lack of blood cells being made in the bone marrow, other organs in the body start to make blood cells. This is usually the spleen and liver. These organs get bigger as they make blood cells. Patients with MF also commonly experience anaemia (low numbers of red blood cells), fatigue, fever and muscle pains. The mainstay of treatment for MF are a class of drug called JAK inhibitors, but there are very limited treatment options for many patients who fail to respond adequately to these. Targeted therapies are drugs that block the growth of cancer cells. They do this by interfering with specific molecules that affect how cancers grow and divide. Immunotherapy drugs use the immune system to find and attack cancer cells.
In this study, combination therapies with novel agents including immunotherapy will focus on determining the promising combinations that provide acceptable safety and efficacy independent of JAK inhibitors. Immunotherapy combinations, such as MBG453 in combination with NIS793, might offer the potential to target MF across genetic heterogeneityREC name
London - City & East Research Ethics Committee
REC reference
20/LO/0827
Date of REC Opinion
30 Jul 2020
REC opinion
Further Information Favourable Opinion